MO-I-1100 is an inhibitor of ASPH (Aspartyl-(Asparaginyl)-β-hydroxylase) enzymatic activity. It suppresses HCC (hepatocellular carcinoma) cell migration, invasion, and anchorage-independent growth, and demonstrates antitumor effects by inhibiting the Notch signaling cascade in HCC. In vitro, it inhibits the viability of FOCUS cells, which exhibit high levels of ASPH expression. In vivo, MO-I-1100 reduces tumor growth and activated Notch 1 signaling in HCC xenograft models.
- Inhibits ASPH enzymatic activity
- Suppresses HCC cell migration, invasion, and anchorage-independent growth
- Exhibits antitumor effects by inhibiting Notch signaling cascade
- Reduces tumor growth in intrahepatic orthotopic xenograft models of HCC